Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results

Zai Lab (NASDAQ:ZLAB) posted its quarterly earnings results on Thursday. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.18, FiscalAI reports. The business had revenue of $106.31 million for the quarter, compared to the consensus estimate of $103.87 million. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.

Here are the key takeaways from Zai Lab’s conference call:

• Positive Sentiment: Zai Lab reported second-quarter net product revenue of $105.8 million, up 11% sequentially, while maintaining a commercially profitable business. Management expects KarXT, potential NRDL inclusions, and continued demand for key brands to support meaningful growth in 2027.
• Positive Sentiment: The DLL3 ADC zoci is advancing rapidly, with a global Phase III second-line small-cell lung cancer trial expected to complete enrollment in the first half of 2027 and a potential U.S. accelerated-approval submission later that year. The company also plans a first-line, chemo-sparing Phase III combination study and expects three registrational programs by year-end.
• Positive Sentiment: ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, is expected to generate initial human pharmacokinetic, pharmacodynamic, safety, and immunogenicity data in the second half of 2026. Zai believes its potential for durable itch reduction, skin clearance, and less frequent dosing could differentiate it in a competitive market.
• Negative Sentiment: Management did not reaffirm its prior goal of reaching overall profitability by the end of 2025, instead indicating that profitability will develop over time as revenue grows and global assets advance. Continued investment in multiple global programs means operating expenses are expected to remain broadly stable through the rest of 2026.
• Neutral Sentiment: The company ended the quarter with $717.5 million in cash and is prioritizing spending on its highest-value programs while streamlining operations and expanding AI use across functions. Additional pipeline catalysts include initial ZL-6201 data expected in the first half of 2027 and an IND filing for the MUC17 T-cell engager ZL-1311 by year-end.

Zai Lab Trading Up 13.7%

ZLAB traded up $2.51 during midday trading on Thursday, hitting $20.88. 1,388,022 shares of the company were exchanged, compared to its average volume of 658,131. The company’s 50 day simple moving average is $18.64 and its 200 day simple moving average is $19.22. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -12.89 and a beta of 0.78. Zai Lab has a 1-year low of $15.96 and a 1-year high of $36.77.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Citigroup cut their price target on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Insider Activity

In related news, Director William Lis sold 7,040 shares of Zai Lab stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $18.09, for a total transaction of $127,353.60. Following the completion of the transaction, the director directly owned 50,437 shares in the company, valued at approximately $912,405.33. This trade represents a 12.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Yajing Chen sold 2,264 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $39,529.44. Following the completion of the transaction, the chief financial officer directly owned 35,691 shares of the company’s stock, valued at $623,164.86. The trade was a 5.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 90,873 shares of company stock valued at $1,730,096 in the last quarter. 4.88% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada lifted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 41.65% of the stock is currently owned by institutional investors.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.